Top Insights
Health
globalreutersSeptember 29, 20241 Mins read
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
globalreutersSeptember 29, 20241 Mins read 
Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA-approved indication for the blockbuster drug.
The post Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Experts Warn of Strong Link Between Alcohol and Six Types of Cancer
A recent report underscores a significant link between excessive alcohol consumption and...
Spinal Stenosis Treatment in India
You will need spinal stenosis treatment in India if you want relief...
Links
Tyler Cowen on the price of Ozempic. Problems with the OMB’s social...
AI Holds Promise, But Concerns Around Costs and Data Remain
The new generation of healthcare AI innovation is promising, but there are...
Leave a comment